A study of nivolumab (Opdivo) in patients with squamous cell carcinoma of the anal canal (SCCA), which recently presented findings at the 2016 World Congress on Gastrointestinal (GI) Cancer, is the first prospective trial to examine immunotherapy agents in the treatment of SCCA.
Approximately 80% to 95% of cases are linked to human papillomavirus (HPV) infection. "The role of HPV in the tumorigenesis of SCCA provides rationale for the use of immune checkpoint agents as a novel therapy for patients with a virally driven disease." noted lead author Cathy Eng, MD, professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center and co-leader of MD Anderson's HPV-related Cancer Moon Shot.
Please read more here.
No comments:
Post a Comment